Recruiting

Genetic Testing

Sponsor:

UCLA

Code:

NCT05746182

Conditions

Pancreatic Neuroendocrine Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Hereditary Cancer Panel

Study Details

Brief summary:

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Conditions

Pancreatic Neuroendocrine Neoplasm

Study ID

NCT05746182

Start date

Apr 7, 2023

Status verified date

Jan, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Histologically confirmed PanNEN.

a. The diagnostic biopsy may have been taken from any site (primary or metastatic).
2. New and existing PanNEN participants will be eligible (any grade, any stage, any age > 18 years).
3. Participants willing and able to comply with the study procedures.

Exclusion Criteria:

1. Inability to provide informed consent.
2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:

1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
2. Active hematologic malignancy.
3. History of allogenic bone marrow transplant or stem cell transplant.

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with Pancreatic Neuroendocrine Neoplasms

Interventions

Hereditary Cancer Panel

UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes

Primary outcome measure

  • Rate of overall pathogenic germline mutations [ Time Frame: Up to 2 years ]

Central Contacts and Locations

Central contacts

Bryan Le

(415) 502-6313bryankhuong.le@ucsf.edu

Locations

University of California, Los Angeles

Recruiting

Los Angeles, California, United States, 90095

Principal Investigator:

Randy Hecht, MD

Univeristy of California, San Diego

Recruiting

San Diego, California, United States, 92093

Principal Investigator:

Paul Fanta, MD

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Bryan Le

415-502-6313bryankhuong.le@ucsf.edu

877-827-3222cancertrials@ucsf.edu

Principal Investigator:

Emily Bergsland, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Jan 26, 2026

Last verified

Jan, 2026

Keywords

  • Genetic Assay
  • Biomarkers

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-01-26.